newsfilter
← Latest News
Business Wire·

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch